Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has received ...

Teleflex (NYSE:TFX) reported second-quarter revenue and adjusted earnings above its expectations, supported by strong growth in its Vascular and Surgical businesses, while slower-than-anticipated ...

Teleflex (TFX) came out with quarterly earnings of $1.76 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $3.73 per share a year ago. These figures are ...

Teleflex quarterly update covers Russell 1000 healthcare operations, medical device products, hospital technologies, global ...

Explore Teleflex FDA-approved plasma platform, healthcare operations, trauma care technologies, product developments, and S&P ...

Combining leading in-house expertise with platform-enhancing investments to accelerate advances in engineering, innovation and manufacturing ...

Military trauma experts say a newly approved plasma product could help expand lifesaving care far from hospitals.

Medical technology company Teleflex (NYSE:TFX) reported Q2 CY2026 results , with sales up 28.9% year on year to $570.3 ...

Medical technology company Teleflex (NYSE:TFX) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with ...

Teleflex reported Q1 2026 continuing operations revenue of $548.3 million, up 32.3% year over year on a GAAP basis, reflecting the impact of acquisitions. On a pro forma adjusted constant currency ...

Teleflex may be enjoying improved profits and sales. But it will still lay off workers and close plants as it restructures in the face of what top executive Benson F. Smith describes as "continuing ...

Teleflex Incorporated has announced a contract with Vizient, Inc. for the supply of its Central Venous Access Catheters and Arterial Catheters, effective January 1, 2025. Vizient, the largest provider ...